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Both SP-D and KL-6/MUC1 are established biomarkers of the interstitial pneumonias, including idiopathic pulmonary ﬁbrosis
(IPF), but the causes and clinical outcomes based on their independent eﬀects are not known. Eleven asymptomatic patients,
detected with honeycombing on high-resolution computed tomography (HRCT), were compared with 17 other IPF outpatients
having slight respiratory symptoms and honeycombing as well. Although SP-D was increased in both groups, KL-6 was
signiﬁcantly higher in the symptomatic IPF group. When the patients (n = 11) having both biomarkers elevated were compared
with the other patients (n = 6) with only SP-D elevated, the distribution of ﬁbrotic lesions with honeycombing on HRCT was
larger and the survival time was shorter in the patients having both biomarkers elevated. Immunohistochemical analysis also
diﬀerentiated these biomarkers in the lung. These results suggest both a cause and the prognostic value of dissociation of these
biomarkers.
1.Introduction
Although the prognosis for patients with idiopathic pul-
monary ﬁbrosis (IPF) is very poor after a diagnosis of
respiratory symptoms, that is, a median survival of 2–
4yrs [1], the natural history of IPF, from the point
of view of asymptomatic status, is not well understood.
According to the American Thoracic Society/European Res-
piratory Society (ATS/ERS) Consensus Statement in 2002,
“respiratory symptoms and abnormalities on pulmonary
function test are required for the diagnosis of IPF in the
absence of surgical biopsy” [2]. Therefore, most of the
patients with IPF reported previously seem to have been
of advanced stage. However, the detection of early stage of
asymptomatic patients with IPF is important for the under-
standing the pathogenesis of this progressive pulmonary
ﬁbrosis, and for developing more eﬀective treatments of
IPF.
Several studies have reported patients in early stages of
interstitial lung disease (ILD) [3–6]. Arakawa et al. followed
dust-exposed patients and reported that honeycombing
required a median of 12 years to develop in normal or near-
normal lungs [3]. Rosas et al. evaluated family members
of patients with familial pulmonary ﬁbrosis to identify
asymptomatic patients and suggested that progression from
early asymptomatic to symptomatic status takes place over
a period of decades [5]. Although radiological ﬁndings on
high-resolution computed tomography (HRCT) has been
reported [3, 6], there is only limited information on the
relevantbiomarkers,suchassurfactant proteinD(SP-D)and
Krebs von den Lungen-6 Antigen/MUC1 (KL-6/MUC1) in
early stages of IPF [4].
SP-D and KL-6/MUC1 are useful biomarkers in the
diagnosis of various ILDs, such as IPF, collagen vascular
disease-associated interstitial pneumonitis, radiation pneu-
monitis, hypersensitivity pneumonitis, pulmonary alveolar2 Pulmonary Medicine
proteinosis, and drug-induced pneumonitis [7, 8]. SP-D
belongs to the collectin subgroup of the C-type lectin
superfamily [9]. Clara cells, nonciliated epithelial cells in the
peripheral airways, and alveolar type II epithelial cells are
known tosecrete theprotein in theairspace [7].KL-6/MUC1
is a circulating high-molecular-weight glycoprotein, classi-
ﬁed as human MUC1 mucin [10]. MUC1 is expressed on
the surface membrane of alveolar type II epithelial cells
and bronchiolar epithelial cells [11]. Most patients with ILD
display elevated SP-D and KL-6/MUC1 in parallel, which
is considered to be due to the fact that both are derived
from regenerated alveolartype II epithelial cellsin interstitial
pneumonias [8, 12]. Although some patients reportedly
exhibitadivergencebetweenSP-DandKL-6/MUC1[13],the
mechanism and the clinical value of each biomarker has not
been clariﬁed yet.
The initial aim of this study was to reveal the charac-
teristics of the biomarkers SP-D and KL-6/MUC1 in early-
stage IPF. In 2002, we found out that asymptomatic patients
with honeycombing on HRCT have elevated SP-D but not
KL-6/MUC1 in their serum. Therefore, as second aim, to
evaluatetheprognosticvalueofthedivergencebetweenSP-D
and KL-6/MUC1, we surveyed the outcome of these patients
for 8–10 years. We also performed an immunohistochemical
study to conﬁrm the dissociation of these biomarkers in the
lung tissues obtained by surgical lung biopsy.
2.MaterialandMethods
2.1. Patients. We conducted a retrospective study of 28
outpatientsatTohokuUniversityHospitalandSendaiKousei
Hospital,Sendai,Japan, between1999–2001.Allpatientsmet
radiological ﬁndings of deﬁnite usual interstitial pneumonia
(UIP)patternonHRCT,(1)subpleural,basalpredominance,
(2)reticularabnormality,(3)honeycombingwith orwithout
traction bronchiectasis, and (4) absence of features listed
as inconsistent with UIP pattern. In addition, none of
these patients had any evident disease, such as collagen
diseases or hypersensitivity pneumonia, reportedly causative
of ILD. Bacteriological examinations were of no clinical
signiﬁcance in all patients. In the 28 patients, two groups,
asymptomatic (n = 11) and symptomatic patients (N =
17), were included. Asymptomatic patients (n = 11) had
no respiratory symptoms, and normal pulmonary function.
Therefore, these patients could not be diagnosed as having
IPF on the basis of ATS/ERS 2002 consensus classiﬁcation
statement [2], but could be in the early stage of IPF. In
asymptomatic patients, some abnormalities on chest X-ray
had been detected in the course of the health examination
system in Japan, which was subsequently conﬁrmed to
meet the HRCT criteria of UIP pattern. In contrast, the
symptomatic patients (n = 17) had certain respiratory
symptoms, such as cough or dyspnea on exertion, but less
than Hugh-Johns level II, at most. They were diagnosed
as having IPF on the basis of 2002 consensus classiﬁcation
statement (clinical n = 15, surgical n = 2) [2]. Next, we
extracted two groups, SP-D (n = 6) and SP-D&KL-6 group
(n = 11), based on the SP-D and KL-6/MUC1 serum levels
(Table 2)fromthese28patients.TheSP-Dgroupwasdeﬁned
Table 1:Characteristicsofasymptomaticandsymptomaticpatients
with honeycombing on HRCT.
Asymptomatic Symptomatic P values
Patients (M/F) 10/1 15/2
Age yrs 67 ± 3
(n = 11)
66 ± 2
(n = 17)
.32
Smoking
Current/Ex/Never 5/2/1 5/4/5 .44
Pack-yrs 33.3 ± 6.3
(n = 8)
33.1 ± 7.6
(n = 14)
.60
VC %pred 96.9 ± 6.1
(n = 9)
88.1 ± 3.6
(n = 15)
.25
FEV1.0/FVC (%) 82.3 ± 3.4
(n = 9)
84 ± 2.2
(n = 15)
.61
DLCO %pred 79.3 ± 6.1
(n = 6)
58.3 ± 5.8
(n = 14)
.031∗
RV/TLC % 32.6 ± 1.8
(n = 5)
34.5 ± 2.0
(n = 15)
.36
Data are presented as mean ± S.E. VC: vital capacity. EFV1.0:f o r c e de x p i r a -
tory volume in one second. FEV: forced expiratory volume. DLCO:d i ﬀusing
capacity of lung for carbon monoxide. RV/TLC: Residual volume/Total lung
capacity. ∗: <.05.
as the patients with a serum SP-D more than two times the
cut oﬀ level (110ng/ml), and serum KL-6/MUC1 less than
the cut oﬀ level (500U/ml), which for SP-D > 220ng/ml and
KL-6/MUC1 < 500U/ml. SP-D&KL-6 group was deﬁned as
the patients with serum SP-D and KL-6/MUC1 more than
two times the cut oﬀ levels (SP-D > 220ng/ml and KL-
6/MUC1 > 1000U/ml).
2.2. Survey of Outcome of the Patients. We surveyed the
outcome of the patients by telephone call or postal mail in
August 2009. We could not contact one patients of each in
SP-D and SP-DKL-6 group.
2.3. Pulmonary Function Tests. Measurements of vital capac-
ity (VC), FVC, FEV1,r a t i oo fF E V 1 to FVC (FEV1.0%), total
lung capacity (TLC), ratio of residual volume (RV) to TLC
(RV/TLC), and the diﬀusing capacity of the lung for carbon
monoxide (DLCO) were made using standard equipment
(CHESTAC-55V;CHESTCo.,Tokyo,Japan) accordingtothe
ATS recommendations [14].
2.4. Collection and Analysis of Blood Samples. Peripheral
venous blood samples were collected between 1999–2001.
Each serum sample was analyzed for SP-D and KL-6/MUC1.
The serum level of SP-D was measured by a commercially
available enzyme-linked immunosorbent assay (ELISA) kit
(Yamasa Co., Japan), as previously described [15]. Serum
KL-6/MUC1 was measured by a commercially available
sandwich ELISA kit (Eisai Co., Japan) [10]. The serum
cut-oﬀ levels were 110ng/ml (SP-D) and 500U/ml (KL-
6/MUC1).
2.5. Analysis of HRCT Scan Imaging. All patients ﬁrst under-
went conventional CT scanning of the chest using 10-mm
thick sections. The HRCT scans also were performed withinPulmonary Medicine 3
twoweeks ofthecollectionofthe bloodsample. The ﬁndings
on HRCT were evaluated by discussion among the authors,
includinga radiologist. On the basis ofpreviousstudy results
[16], we measured the distribution of ﬁbrotic lesions with
honeycombing in three levels (aortic arch, carina, and the
top of diaphragm) on HRCT images for each patient using
a computerized image-analyzer system (NIH image).
2.6. Immunohistochemistry for SP-D and KL-6. Specimens of
the three IPF lung tissues were obtained by video-assisted
thoracoscopic surgery at Tohoku University Hospital. Lung
specimens were ﬁxed in 10% buﬀered formalin for 18h
a n de m b e d d e di np a r a ﬃn for immunohistochemistry. The
antibody against KL-6 was provided by Sanko Junyaku
Co., Ltd. (Tokyo, Japan) and SP-D by YAMASA (Tokyo,
Japan); both of which are commonly used for detecting the
serum levelsof these biomarkers. An antihuman podoplanin
monoclonal antibody (AngioBio Co., Del Mar, CA) was
used for detecting lymphatic endothelial cells, and antibod-
ies against human CD34 (Nichirei) and von Willebrand
factor (vWF) (Nichirei) were used for endothelial cells
in the lung. The antigen-antibody complex was visualized
using Vector Red (Vector Laboratories, Burlingame, CA)
and/or diaminobenzidine (DAB), and counterstained with
elastica-Goldner stain, modiﬁed elastica-Mason stain. For
immunoﬂuorescentstaining,theAlexaFluorDye(Molecular
Probes, Invitrogen) appropriate for each antibody was used
according to the manufacturer’s instructions.
2.7. Statistical Analysis. For comparison between asymp-
tomatic and symptomatic patients (Table 1), SP-D and SP-
D&KL-6 group (Table 2), data were analyzed by Mann-
Whitney nonparametric test. For comparison of SP-D
and KL-6/MUC1 between asymptomatic and symptomatic
patients, data were analyzed by paired t-test. Diﬀerences of
the distribution of ﬁbrotic lesions with honeycombing in
S P - Da n dS P - D & K L - 6g r o u pw e r ec o m p a r e dw i t ht h eu s e
of paired t-test. The survival duration was estimated using
the Kaplan-Meier method, and comparison was made using
the log rank test. In all tests, P values < .05 were considered
statistically signiﬁcant.
3.Results
3.1. Serum SP-D Is Elevated Even in Asymptomatic Patients
with Honeycombing on HRCT. The clinical characteristics
and pulmonary function data are summarized in Table 1.
The ageoftheasymptomatic patientsrangedfrom 49–80yrs,
and that of the symptomatic patients ranged from 46–76yrs.
In the pulmonary function data, the DLCO was lower in the
symptomatic IPF patients than that in the asymptomatic
patients.
The level of serum SP-D and KL-6/MUC1 was com-
pared among asymptomatic and symptomatic IPF patients
(Figure 1). The level of serum SP-D was elevated in both
asymptomatic and symptomatic IPF patients (235.8 ± 41.0,
310.7 ± 31.1ng/ml, resp.). The levels of serum KL-6/MUC1
in asymptomatic and symptomatic IPF patients were 423.9
± 61.0, 1256.2 ± 143.5U/ml, respectively. Although the
Table 2: Characteristicsofpatients inSP-DandSP-D&KL-6 group.
SP-D group SP-D&KL-6
group
P values
Age yrs 71 ± 2.2
(n = 6)
66 ± 2.1
(n = 11)
.19
Pack-yrs 28.6 ± 11.5
(n = 4)
31.0 ± 12.2
(n = 8)
.72
VC %pred 102.4 ± 7.3
(n = 5)
82.5 ± 4.5
(n = 9)
.045∗
FEV1.0/FVC (%) 82.9 ± 5.1
(n = 5)
87.3 ± 2.1
(n = 9)
.69
DLCO %pred 71.6 ± 16.5
(n = 3)
61.6 ± 7.8
(n = 9)
.051
RV/TLC (%) 34.9 ± 4.1
(n = 3)
32.9 ± 1.7
(n = 9)
.40
SP-D ng/ml 336 ± 40.3
(n = 6)
375 ± 30.8
(n = 11)
.48
KL-6/MUC1 U/ml 393 ± 20.5
(n = 6)
1439 ± 169
(n = 11)
<.001∗
HRCT scan ﬁbrotic
area (%)
Aortic arch 0.7 ± 0.2
(n = 6)
14.9 ± 4.7
(n = 11)
<.001∗
Carina 1.1 ± 0.5
(n = 6)
15.8 ± 5.6
(n = 11)
<.001∗
Top of
diaphragm
5.4 ± 2.4
(n = 6)
33.4 ± 7.6
(n = 11)
<.001∗
Data are presented as mean ± S.E. SP-D group: SP-D > 220ng/ml and KL-6
< 500U/ml; SP-D&KL-6 group: SP-D > 220ng/ml and KL-6 > 1000U/ml.
∗: P<. 05.
mean level of KL-6/MUC1 in asymptomatic patients was
higher in comparison with those in normal volunteers (258
± 131U/ml) reported in previous study [17], most of the
asymptomatic patients had a normal range of KL-6/MUC1.
3.2. Patients with Elevated SP-D Independent of KL-6 Had
Limited Fibrotic Lesions with Honeycombing on HRCT. To
analyze the clinical value of SP-D and KL-6/MUC1, we
extracted two groups from these 28 patients by the elevated
biomarkers, an SP-D group (n = 6) and SP-D&KL-6 (n =
11) group, because none of these patients had high KL-
6/MUC1 with a normal range of SP-D. The SP-D group con-
sisted of ﬁve asymptomatic patients and one symptomatic
patient. The SP-D&KL-6 group consisted of eleven patients,
all symptomatic. The clinical characteristics and pulmonary
function data of these patients are summarized in Table 2.
The age of the patients in the SP-D group ranged from 66–
80yrs, and in the SP-D&KL-6 group ranged from 49–74yrs.
In the pulmonary function data, vital capacity was lower in
the SP-D&KL-6 group than the SP-D group.
To analyze the relation of biomarkers and ﬁbrotic
lesions with honeycombing on HRCT, we measured the
distributional area of ﬁbrotic lesions with honeycombing
in three levels of the HRCT of each patient (Upper; aortic
arch, Middle; carina, Lower; top of diaphragm). The mean
percentage of the area of ﬁbrotic lesions with honeycombing4 Pulmonary Medicine
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Figure 1: Comparisonof serum levels of SP-D and KL-6/MUC1 between asymptomatic patients with honeycombingand symptomatic IPF
patients. Both groups have elevated SP-D without statisticdiﬀerence, but KL-6/MUC1 was signiﬁcantlyhigher in symptomatic IPF patients.
Dotted lines represent mean values of SP-D (110ng/ml) and KL-6/MUC-1 (500U/ml).
wassigniﬁcantlylowerintheSP-DgroupthantheSP-D&KL-
6g r o u pTable 2.
3.3.ThePatientswithOnlyanElevatedSP-DLevelHadLonger
Survival. We surveyed the clinical outcome of patients in
the SP-D group and the SP-D&KL-6 group for 8–10 years
after initial detection. Because we could not contact one
patient in each group, we compared the overall survival
between the SP-D only group (n = 5) and the SP-D&KL-
6g r o u p( n = 10) by Kaplan-Meier analysis (Figure 2). Two
of ﬁve patients in the SP-D group died of pneumonia. One
patient died of unknown cause. Two patients were alive
with slight respiratory symptoms. In contrast, four of ten
patients in the SP-D&KL-6 group died of acute exacerbation
ofIPF; one patient died of progression ofchronic respiratory
failure, one patient died of pneumonia, one patient died of
pancreas cancer, and two patients died of unknown causes.
One patient is still alive.
3.4. Distribution of SP-D and KL-6/MUC1 in IPF Lungs.
There is a clear diﬀerence in the immunohistochemical
distribution pattern between SP-D and KL-6/MUC1. While
both of the biomarkers are produced by alveolar type II cells
andbronchiolarepithelialcells,theimmunoreactivityforSP-
D is cytoplasmic, while KL-6 is distributed at extracellular
sites facing the alveolar space or airway space (Figures 3(a)
and 3(b)). In IPF lung tissues, regenerated type II epithelial
cells are increased in number and immunoreactive intensity
of SP-D of these cells are also increased (Figures 3(c) and
3(d)). Most of these epithelial cells are in close contact with
alveolar capillaries (Figures 3(c) and 3(d)). In honeycomb
lesions, KL-6/MUC1 is more broadly distributed inside the
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Figure 2: The Kaplan-Meier survival curves of patients with
honeycombing in SP-D and SP-D&KL-6 groups. Patients in SP-D
group (in red) had longer survival (mean survival time, MST; 3117
days) than those in SP-D&KL-6 group (in blue) (MST; 1232 days)
(P = .0417).
cystic space than SP-D (Figures 3(e) and 3(f)). Interestingly,
bothKL-6andSP-Dareobservedinthelymphatics,butKL-6
was notdistributed in thepulmonary veins, where only SP-D
was included (Figure 4).
4.Discussion
It was shown here that (1) the serum level of KL-6/MUC1
was maintained within the normal range in dissociationPulmonary Medicine 5
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Figure 3: Immunohistochemical distribution of SP-D and KL-6/MUC1 in control and IPF lungs. ((a) and (b)) In control lungs, alveolar
type II epithelial cells show cytoplasmic staining for SP-D (in red). In contrast, KL-6/MUC1 (in green, (b)) distributes extracellular surface
facing alveolar space without cytoplasmic or basal-lateral side expression. The dotted square in (a) is the same section with (b) observed by
ﬂuorescence (scale bar = 10μm). (c) Double immunohistochemistry of SP-D (in brown) and CD34-positive alveolar capillary endothelial
cells (in red) in IPF lung tissues. The alveolar type II epithelial cells with SP-D expression are always in close contact with alveolar capillaries
(indicated by arrows).Counter stainingby elastic-Goldner staining(scalebar = 10μm). (d) In IPF lung tissues, regenerated type II epithelial
cells areincreased with more intenseexpression of SP-D(in red) thancontrollungs.These increasedtype IIepithelialarealsoinclosecontact
withalveolarcapillaries(ingreen). Nuclei arestainedinblue(scalebar =10μm).((e),(f))InhoneycombcystsinIPFlings,thickmucuswith
immunoreactive for KL-6/MUC1 (in brown, (e)) were accumulated in contrast to SP-D (in brown, (f)). Counterstained by elastica-Goldner
staining (scale bars = 100μm).
with the SP-D level, which was elevated in asymptomatic
patients with honeycombing on HRCT, (2) these patients
with high SP-D but low KL-6 in their serum exhibited
prolonged survival, (3) there are obvious diﬀerences in the
distribution patterns between SP-D and KL-6/MUC1 in the
IPF lung, especially in the clearance route, which may cause
the observed dissociation between these biomarkers.
The ﬁnding of honeycombing on HRCT is believed to be
mostly associated with usual interstitial pneumonia (UIP),
as it is reported that honeycombing in at least one lobe6 Pulmonary Medicine
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Figure 4: Immunohistochemistry of SP-D and KL-6/MUC1 in
IPF lungs. Double-ﬂuorescent immunohistochemistry for SP-D
(in red) and KL-6/MUC1 (in green) in IPF lung tissues revealed
SP-D-positive materials within both pulmonary veins (PV) and
lymphatics (L). In contrast, KL-6/MUC1 was not included in
pulmonary veins but only in lymphatics (scale bars = 10μm).
indicate UIP, with a 90% sensitivity and 86% speciﬁcity [18].
In this study, we enrolled the asymptomatic patients with
honeycombing in the subpleural and basal lungs as having
early-stage-IPF.Inthesepatients,theserumlevelofSP-Dwas
signiﬁcantly high, even though the KL-6 level stayed within
the normal range. These results indicate that serum SP-D is a
more sensitive biomarker than serum KL-6/MUC1 to detect
early IPF and has also been reported to be able to detect
the early changes of ILD in patients with systematic sclerosis
[19].
Our survey of the survival of these patients clearly noted
that patients with a high level of SP-D but low KL-6 in their
serum had a better prognosis. Several studies have showed
the prognostic value of the biomarkers, SP-A, SP-D, and
KL-6 at the initial visit [7, 10, 20, 21], but no studies have
referred the clinical outcomes related to the dissociation of
the serum levels of SP-D and KL-6. Our results indicate
that KL-6 is a better prognostic marker than SP-D in IPF
patients.
The diﬀerent mechanistic roles of the biomarkers SP-D
and KL-6 are explained in part from the immunohistochem-
ical study results, which revealed the diﬀerent distribution
patterns of these biomarkers in IPF lungs (Supplement
Figure 1). KL-6 is expressed at the extracellular surface of
alveolar type II cells and bronchiolar epithelial cells, and
from these cells is released into the alveolar lining ﬂuid,
accumulated in honeycomb cysts. Since KL-6 is a high
molecularweight mucin-likeglycoprotein(molecularweight
> 1,000 KD) [17] ,o u rr e s u l t ss h o w i n gK L - 6i sf o u n di n
the lymphatics, but not in the pulmonary veins, may be
reasonable in that KL-6 is too large to be cleared by the
alveolar capillaries, and is cleared by the lymphatics only
[22]. In contrast, SP-D is distributed in the cytoplasm of
these cells, and SP-D is found in both the pulmonary
lymphatics and pulmonary veins. Because SP-D is a very
small molecule (43KD), consisting of four trimeric subunits
[23], SP-D or its fragments may be absorbed from alveolar
capillary endothelial cells, which are always in close contact
with alveolartype II epithelial cells[24].In addition, because
the interlobular lymphatics chieﬂy working for alveolar
clearance is reduced in IPF lungs [22], it may be reasonable
that the KL-6/MUC1 in the alveolar space is delayed to
be cleared and delivered to serum of IPF patients. These
ﬁndings are thought to explain why SP-D is elevated in
asymptomatic patients and that KL-6 is elevated in the later
stages.
There are several limitations in our study. First, the
number of subjects in this study is low. And we did not
evaluate dyspnea quantiﬁcation by means of scales, such
as MRC, in initial subjects enrollment. Second, we could
not analyze changes of lung function from baseline, because
of retrospective study. Therefore, we could not evaluate
regression analysis between biomarkers concentration and
lung functional changes from baseline.
In conclusion, SP-D and KL-6 are useful biomarkers for
diﬀerentiating patients with honeycombing on HRCT into
thestableandprogressivestages,whichwouldinformclinical
implication for IPF.
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